IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES

被引：0
|
作者：
Choueri, Toni K. [1 ]
Fishman, Mayer N. [2 ]
Escudier, Bernard [3 ]
McDermott, David F. [4 ]
Kluger, Harriet [5 ]
Stadler, Walter M. [6 ]
Perez-Gracia, Jose L. [7 ]
McNeel, Douglas [8 ]
Curti, Brendan [9 ]
Harrison, Michael R. [10 ]
Plimack, Elizabeth R. [11 ]
Appleman, Leonard [12 ]
Fong, Lawrence [13 ]
Drake, Charles G. [14 ]
Young, Tina C. [15 ]
Chasalow, Scott D. [15 ]
Ross-Macdonald, Petra [15 ]
Simon, Jason S. [15 ]
Walker, Dana [15 ]
Sznol, Mario [5 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] Yale Canc Ctr, New Haven, CT USA
[6] Univ Chicago, Med, Chicago, IL 60637 USA
[7] Univ Navarra Clin, Pamplona, Spain
[8] Univ Wisconsin, Dept Med, Madison, WI USA
[9] Providence Portland Med Ctr, Providence Canc Ctr, Portland, OR USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[13] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[14] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
Asia-Pacific Journal of Clinical Oncology | 2015年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
189
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [1] Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    McDermott, David F.
    Kluger, Harriet M.
    Stadler, Walter Michael
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan D.
    Harrison, Michael Roger
    Plimack, Elizabeth R.
    Appleman, Leonard Joseph
    Fong, Lawrence
    Drake, Charles G.
    Young, Tina C.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Simon, Jason S.
    Walker, Dana
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    McDermott, David F.
    Drake, Charles G.
    Kluger, Harriet
    Stadler, Walter M.
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan
    Harrison, Michael R.
    Plimack, Elizabeth R.
    Appleman, Leonard
    Fong, Lawrence
    Albiges, Laurence
    Cohen, Lewis
    Young, Tina C.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Srivastava, Shivani
    Jure-Kunkel, Maria
    Kurland, John F.
    Simon, Jason S.
    Sznol, Mario
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5461 - 5471
  • [3] Association of microbiome to nivolumab response in metastatic renal cell carcinoma (mRCC)
    Maia, Manuel
    Poroyko, Valeriy
    Won, Hae
    Bergerot, Paulo
    Almeida, Lorena
    Dizman, Nazli
    Hsu, JoAnn
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [4] Peripheral immunomodulatory changes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab
    Almeida, Lorena
    Maia, Manuel
    Won, Haejung
    Moreira, Dayson
    Bergerot, Paulo
    Kortylewski, Marcin
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] Association of microbiome and plasma cytokine dynamics to nivolumab response in metastatic renal cell carcinoma (mRCC).
    Maia, Manuel C.
    Poroyko, Valeriy
    Won, Haejung
    Almeida, Lorena
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Hsu, Joann
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] Clinical outcomes in patients with chronic hepatitis C and metastatic renal cell carcinoma (mRCC) after treatment with nivolumab.
    Tsimafeyeu, Ilya
    Gafanov, Rustem
    Semenova, Anna
    Oganesyan, Ani
    Bondarenko, Anastasia
    Safina, Sufia
    Zakurdaeva, Kristina
    Protsenko, Svetlana
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 32 - 32
  • [7] Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard J.
    Kim, Jenny J.
    Kluger, Harriet M.
    Stadler, Walter Michael
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan D.
    Harrison, Michael Roger
    Plimack, Elizabeth R.
    Appleman, Leonard Joseph
    Fong, Lawrence
    Drake, Charles G.
    Cohen, Lewis J.
    Srivastava, Shivani
    Jure-Kunkel, Maria
    Hong, Quan
    Kurland, John F.
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
    Silva, C. Alves Costa
    Derosa, L.
    Dalban, C.
    Colomba, E.
    Negrier, S.
    Chevreau, C. M.
    Gravis, G.
    Oudard, S. M.
    Laguerre, B.
    Barthelemy, P.
    Borchiellini, D.
    Gross-Goupil, M.
    Geoffrois, L.
    Rolland, F.
    Thiery-Vuillemin, A.
    Joly, F.
    Ladoire, S.
    Tantot, F.
    Escudier, B.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S710 - S710
  • [10] Real-world (RW) clinical outcomes for metastatic renal cell carcinoma (mRCC)
    George, S.
    Faccone, J.
    Huo, S.
    Zhang, Y.
    Stwalley, B.
    Hamilton, M.
    Le, T. K.
    Ejzykowicz, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S701 - S702
12345